Given the remarkable sensitivity to ICIs that we have observed in murine tumors overexpressing MerTK and pro-inflammatory TIME seen in the human KOALA and TMA, we propose tumor-bound MerTK as an additional biomarker to predict patient response to ICI treatment and expand the number of patients who may be eligible to receive life-saving treatment. This evidence concerns the gene MERTK and neoplasm.